Abstract

Histone deacetylase (HDAC) 2 plays a vital role in modifying histones to mediate inflammatory responses, while HDAC2 itself is commonly regulated by post-translational modifications. Small ubiquitin-related modifier (SUMO), as an important PTM factor, is involved in the regulation of multiple protein functions. Our previous studies have shown that carbocisteine (S-CMC) reversed cigarette smoke extract (CSE)-induced down-regulation of HDAC2 expression/activity in a thiol/GSH-dependent manner and enhanced sensitivity of steroid therapy. However, the mechanism by which S-CMC regulates HDAC2 is worth further exploring. Our study aimed to investigate the relationships between HDAC2 sumoylation and its deacetylase activity under oxidative stress and the molecular mechanism of S-CMC to regulate HDAC2 activity that mediates inflammatory responses in human bronchial epithelial cells. We found that modification of HDAC2 by SUMO1 and SUMO2/3 occurred in 16HBE cells under physiological conditions, and CSE induced SUMO1 modification of HDAC2 in a dose and time-dependent manner. K462 and K51 of HDAC2 were the two major modification sites of SUMO1, and the K51 site mediated deacetylation activity and function of HDAC2 on histone H4 that regulates IL-8 secretion. S-CMC inhibited CSE-induced SUMO1 modification of HDAC2 in the presence of thiol/GSH, increased HDAC activity, and decreased IL-8 expression. Our study may provide novel mechanistic explanation of S-CMC to ameliorate steroid sensitivity treatment in chronic obstructive pulmonary disease.

Highlights

  • Histone deacetylase (HDAC) 2 plays a crucial role in modifying histones to regulate the expression of inflammatory genes (Barnes, 2005, 2009; Ito et al, 2005)

  • Cell lysates of normal 16HBE cells were subjected to immunoprecipitation using an antibody against HDAC2, followed by western blotting using an antibody against SUMO1

  • The same band at ∼100 kD was observed by reverse immunoprecipitation experiment (Figure 1B), suggesting that HDAC2 is covalently modified by SUMO1 under a physiological condition

Read more

Summary

Introduction

Histone deacetylase (HDAC) 2 plays a crucial role in modifying histones to regulate the expression of inflammatory genes (Barnes, 2005, 2009; Ito et al, 2005). Our previous studies have shown that carbocisteine (S-CMC), an anti-oxidant agent extensively used as adjunctive therapy in the treatment of chronic obstructive pulmonary disease (COPD), could reverse the downregulation of HDAC2 induced by oxidative stress and enhance the sensitivity of human alveolar epithelial cells to glucocorticoid (GC) treatment (Song et al, 2015). It remains to be understood regarding the mechanism by which S-CMC ameliorates HDAC2 expression and/or activity. These chemical modifications cause a variety of structural and functional alteration that mediate biological and/or pathological process (Banks et al, 2000; Mann and Jensen, 2003; Segré and Chiocca, 2011; Woodsmith et al, 2013; Lee and Kim, 2015)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call